Company Encyclopedia
View More
name
QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS
74907L409.US
1.813 T
74907L409.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Quoin Pharmaceuticals Ltd - Files For Offering Of Up To 10.05 Million Adss - SEC Filing

    Quoin Pharmaceuticals Ltd :QUOIN PHARMACEUTICALS LTD - FILES FOR OFFERING OF UP TO 10.05 MILLION ADSS - SEC FILING

    Reuters·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%
    Reuters·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study

    Quoin Pharmaceuticals Ltd is conducting a clinical study on QRX003 lotion for treating Netherton syndrome, a genetic skin disorder. The study evaluates the lotion's effectiveness and safety over 12 weeks, focusing on symptom improvement. It began on April 7, 2025, and is currently recruiting participants. Positive results could enhance Quoin's market position and influence its stock performance, given the niche market for Netherton syndrome treatments.

    Tip Ranks·
    US
    QNRX
    +41.40%
    Tip Ranks·
    US
    QNRX
    +41.40%

    Why Quoin Pharmaceuticals Is Rising In Pre-market?

    Quoin Pharmaceuticals (QNRX) has seen an 8% rise in pre-market trading following the FDA's grant of Orphan Drug Designation for its lead product candidate, QRX003, aimed at treating Netherton Syndrome. This designation complements a similar one from the European Medicines Agency in May 2025. QRX003 is currently undergoing pivotal clinical trials, with enrollment expected to finish in Q1 2026 and top-line data anticipated in the latter half of 2026, leading to an NDA submission later that year.

    rttnews·
    US
    74907L409
    0.00%
    rttnews·
    US
    74907L409
    0.00%

    Crude Oil Falls Over 4%; Quoin Pharmaceuticals Shares Spike Higher

    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 2.5% on Friday. The Dow traded up 1.26% to 45,772.50 while the NASDAQ rose 2.46% to 22,459.24. The S&P 500 also rose, gaining, 1.79% to 6,614.73. Consumer staples shares jumped by 0.6% on Friday.

    Benzinga·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%
    Benzinga·
    US
    74907L409
    0.00%
    US
    QNRX
    +41.40%

    Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On?

    Quoin Pharmaceuticals (NASDAQ:QNRX) shares surged 149.14% to $20.40 following the announcement of a private placement financing of up to $104.5 million. The deal includes an initial funding of $16.8 million and will involve issuing American Depositary Shares and pre-funded warrants. Proceeds will support general corporate purposes, including R&D for the QRX003 drug. The financing is expected to close around October 14, and the offering was priced at a premium to the previous closing price of $8.16.

    Benzinga·
    US
    QNRX
    +41.40%
    US
    74907L409
    0.00%
    Benzinga·
    US
    QNRX
    +41.40%
    US
    74907L409
    0.00%